Publications by authors named "Michael Mathisen"

Claim this Profile
E
Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial.
Solange Peters, Shirish M Gadgeel, Tony Mok, Ernest Nadal, Saadettin Kilickap, Michael Mathisen

Nat Med· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-dose alectinib for fusion-positive non-small cell lung cancer in the Blood First Assay Screening Trial.
Rafal Dziadziuszko, Nir Peled, Tony Mok, Solange Peters, Santiago Ponce Aix, Michael S Mathisen

Contemp Oncol (Pozn)· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial.
Solange Peters, Rafal Dziadziuszko, Alessandro Morabito, Enriqueta Felip, Shirish M Gadgeel, Michael S Mathisen

Nat Med· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive Cohort.
Rafal Dziadziuszko, Tony Mok, Solange Peters, Ji-Youn Han, Jorge Alatorre-Alexander, Michael S Mathisen

J Thorac Oncol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Itraconazole, a Potent CYP3A4 Inhibitor, on the Steady-State Pharmacokinetics of Vemurafenib in Patients With BRAF Mutation-Positive Malignancies.
Weijiang Zhang, Michael Mathisen, Grant R Goodman, Harper Forbes, Yuyao Song

Clin Pharmacol Drug Dev· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to price and value in cancer care.
Jagpreet Chhatwal, Michael S Mathisen, Hagop M Kantarjian

Cancer· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Are high drug prices for hematologic malignancies justified? A critical analysis.
Jagpreet Chhatwal, Michael Mathisen, Hagop Kantarjian

Cancer· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Having "Skin in the Game" and Allowing Cross-Border Importation of Drugs to Lower High Prices of Cancer Drugs.
Hagop Kantarjian, Michael S Mathisen, Jeffrey H Lipton

JAMA Oncol· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The ever-evolving landscape of candidaemia in patients with acute leukaemia: non-susceptibility to caspofungin and multidrug resistance are associated with increased mortality.
Emily Wang, Dimitrios Farmakiotis, Daisy Yang, Deborah A McCue, Hagop M Kantarjian, Michael S Mathisen

J Antimicrob Chemother· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemia.
Michael S Mathisen, Hagop M Kantarjian, Jorge Cortes, Elias J Jabbour

Blood Rev· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy.
Elias Jabbour, Naval Daver, Richard Champlin, Michael Mathisen, Betul Oran

Am J Hematol· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Emerging drugs for acute lymphocytic leukemia.
Michael S Mathisen, Hagop M Kantarjian, Elias J Jabbour

Expert Opin Emerg Drugs· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acute lymphoblastic leukemia in adults: encouraging developments on the way to higher cure rates.
Michael S Mathisen, Hagop Kantarjian, Deborah Thomas, Susan O'Brien, Elias Jabbour

Leuk Lymphoma· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer drugs in the United States: Justum Pretium--the just price.
Hagop M Kantarjian, Tito Fojo, Michael Mathisen, Leonard A Zwelling

J Clin Oncol· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clofarabine does not negatively impact the outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation.
Michael S Mathisen, Hagop Kantarjian, Elias Jabbour, Guillermo Garcia-Manero, Farhad Ravandi

Clin Lymphoma Myeloma Leuk· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: a retrospective case-control study.
Elias Jabbour, Michael S Mathisen, Guillermo Garcia-Manero, Richard Champlin, Uday Popat

Am J Hematol· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Ocular granulocytic sarcoma: a case report and literature review of ocular extramedullary acute myeloid leukemia.
Maro Ohanian, Gautam Borthakur, Alfonso Quintas-Cardama, Michael Mathisen, Jorge E Cortés

Clin Lymphoma Myeloma Leuk· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
1
10 years of progress in chronic myelogenous leukemia.
Elias Jabbour, Michael S Mathisen, Susan O'Brien

J Natl Compr Canc Netw· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of adult acute lymphoblastic leukemia (ALL) with a focus on emerging investigational and targeted therapies.
Michael S Mathisen, Elias Jabbour, Hagop M Kantarjian

Oncology (Williston Park)· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of tosedostat, a novel, oral agent for elderly patients with relapsed or refractory acute myeloid leukemia: a review of the Phase II OPAL trial.
Michael S Mathisen, Farhad Ravandi

Future Oncol· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Horse versus rabbit antithymocyte globulin in aplastic anemia.
Michael S Mathisen, Farhad Ravandi

N Engl J Med· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of tyrosine kinase inhibitors in the management of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Michael S Mathisen, Susan O'Brien, Deborah Thomas, Jorge Cortes, Hagop Kantarjian

Curr Hematol Malig Rep· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The tumor lysis syndrome.
Michael S Mathisen

N Engl J Med· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytarabine dose for acute myeloid leukemia.
Michael S Mathisen

N Engl J Med· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mutant BCR-ABL clones in chronic myeloid leukemia.
Michael S Mathisen, Hagop M Kantarjian, Jorge Cortes, Elias Jabbour

Haematologica· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis